Targeting senescent hepatocytes for treatment of metabolic dysfunction-associated steatotic liver disease and multi-organ dysfunction
Abstract Senescent hepatocytes accumulate in metabolic dysfunction-associated steatotic liver disease (MASLD) and are linked to worse clinical outcomes. However, their heterogeneity and lack of specific markers have made them difficult to target therapeutically. Here, we define a senescent hepatocyt...
Saved in:
| Main Authors: | Kuo Du, David S. Umbaugh, Liuyang Wang, Ji Hye Jun, Rajesh K. Dutta, Seh Hoon Oh, Niansheng Ren, Qiaojuan Zhang, Dennis C. Ko, Ana Ferreira, Jon Hill, Guannan Gao, Steven S. Pullen, Vaibhav Jain, Simon Gregory, Manal F. Abdelmalek, Anna Mae Diehl |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-03-01
|
| Series: | Nature Communications |
| Online Access: | https://doi.org/10.1038/s41467-025-57616-w |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Antifibrotic therapies for metabolic dysfunction-associated steatotic liver diseaseKeypoints
by: Robert F. Schwabe, et al.
Published: (2025-08-01) -
Unmet needs of metabolic dysfunction – Associated “fatty or steatotic” liver disease
by: Yu-Ming Cheng, et al.
Published: (2025-04-01) -
Liver TET1 promotes metabolic dysfunction-associated steatotic liver disease
by: Hongze Chen, et al.
Published: (2025-03-01) -
Rearrangement of the liver ubiquitome and NEDDylome in metabolic dysfunction-associated steatotic liver disease
by: Teresa C. Delgado, et al.
Published: (2025-08-01) -
The new definition of metabolic dysfunction-associated steatotic liver disease: the role of ultrasound and elastography
by: Xinrui Jin, et al.
Published: (2025-05-01)